RxDoctor Payments Data

Jeffrey Gong, DO

Internal Medicine · Little Egg Harbor Twp, NJNPI 1780771626

Payments from drug & device makers

$1,765in general payments, 2019–2025

Across 97 payments — averaging $18.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$270
  • Sunovion Pharmaceuticals Inc.$209
  • Novo Nordisk$173
  • Lilly USA, LLC$137
  • Kowa Pharmaceuticals America, Inc.$131
  • Pfizer$111
  • plus $736 from 16 others

What the payments were for

  • Food & beverage$1,75099%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,765 in reported general payments places this provider in the 75th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$56,098
Medicare patients
199
Services billed
486

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate54$61,147
EliquisApixaban158$51,008
JardianceEmpagliflozin25$42,070
XareltoRivaroxaban19$20,377
MounjaroTirzepatide19$19,666
TradjentaLinagliptin21$19,307
MyrbetriqMirabegron51$9,570
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$7,083
Atorvastatin Calcium687$6,536
Pantoprazole Sodium429$4,657
Levothyroxine Sodium426$3,760
Amlodipine Besylate502$3,623
Pravastatin Sodium161$3,521
BrilintaTicagrelor31$3,455
Divalproex Sodium33$3,377

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$42$61,37746 claims
MerckJanuvia$24$61,14754 claims
PfizerEliquis$111$51,008158 claims
Johnson & JohnsonXarelto$89$20,37719 claims
Lilly USA, LLCMounjaro$137$19,66619 claims
Astellas Pharma US IncMyrbetriq$24$9,57051 claims
AstraZenecaBrilinta$270$3,45531 claims
AbbVieSynthroid$25$1,69521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Little Egg Harbor Twp

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →